Ang1005 trial

Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

Read our disclaimer for details. Last Update Posted : September 10, See Contacts and Locations. Study Description. This is an open-label Phase 3 study to see if ANG can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated brain metastases.

MedlinePlus related topics: Breast Cancer. FDA Resources. Arms and Interventions. Federal Government. Read our disclaimer for details. Last Update Posted : February 25, Study Description. This is a Phase 2 study to see if an investigational drug, ANG, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics PK of ANG in patients. Detailed Description:. FDA Resources.

Arms and Interventions. ANG, with or without bevacizumab, administered to bevacizumab-refractory recurrent GBM participants. For participants enrolled in the bevacizumab-refractory recurrent GBM arm Arm 2 , treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.

Outcome Measures. To determine the number of patients without progression at 3, 6 and 12 months in Arms 1 and 3 To determine the number of patients without progression at 6 and 12 months in Arm 2. To determine the median progression-free survival in each arm. To determine the median duration of response in each arm. To determine the median overall survival in each arm. Founded in , Angiochem maintains headquarters in Montreal, Canada.

For more information, please contact: Mr. John Huss Executive Chairman jhuss angiochem. Privacy Policy Terms of Use.